Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $32.2 million.

  • Xeris Biopharma Holdings' Net Cash Flow rose 201081.26% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.3 million, marking a year-over-year increase of 15233.85%. This contributed to the annual value of $4.1 million for FY2024, which is 10744.88% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Net Cash Flow is $32.2 million, which was up 201081.26% from $845000.0 recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Net Cash Flow peaked at $42.2 million during Q4 2022, and registered a low of -$71.0 million during Q1 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$27000.0 (2023), whereas its average is $3.1 million.
  • In the last 5 years, Xeris Biopharma Holdings' Net Cash Flow plummeted by 29446.59% in 2023 and then skyrocketed by 575185.19% in 2024.
  • Xeris Biopharma Holdings' Net Cash Flow (Quarter) stood at $7.8 million in 2021, then skyrocketed by 442.41% to $42.2 million in 2022, then tumbled by 49.99% to $21.1 million in 2023, then crashed by 41.3% to $12.4 million in 2024, then soared by 160.0% to $32.2 million in 2025.
  • Its Net Cash Flow stands at $32.2 million for Q3 2025, versus $845000.0 for Q2 2025 and -$13.2 million for Q1 2025.